Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Assets (2020 - 2026)

RxSight filings provide 6 years of Assets readings, the most recent being $311.8 million for Q4 2025.

  • On a quarterly basis, Assets fell 2.12% to $311.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $311.8 million, a 2.12% decrease, with the full-year FY2025 number at $311.8 million, down 2.12% from a year prior.
  • Assets hit $311.8 million in Q4 2025 for RxSight, up from $308.5 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $318.6 million in Q4 2024 to a low of $94.9 million in Q2 2021.
  • Median Assets over the past 5 years was $195.3 million (2023), compared with a mean of $224.4 million.
  • Biggest five-year swings in Assets: surged 91.43% in 2021 and later dropped 23.57% in 2022.
  • RxSight's Assets stood at $192.7 million in 2021, then dropped by 22.08% to $150.2 million in 2022, then rose by 21.57% to $182.5 million in 2023, then surged by 74.51% to $318.6 million in 2024, then decreased by 2.12% to $311.8 million in 2025.
  • The last three reported values for Assets were $311.8 million (Q4 2025), $308.5 million (Q3 2025), and $309.0 million (Q2 2025) per Business Quant data.